Maxim Group analyst Michael Diana has maintained their neutral stance on SURG stock, giving a Hold rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Diana’s rating is based on several factors that reflect the current uncertainties surrounding SurgePays’ business model and financial outlook. The company’s recent financial results showed a decline in revenue and a net loss, which were below market expectations. This underperformance was partly due to the delayed impact of their Lifeline program, which only began to gain traction in the third quarter of 2025.
Furthermore, while SurgePays has initiated strong revenue guidance for 2025, there are concerns about the sustainability of the recent sign-ups and the overall economics of the Lifeline program. The program involves upfront costs for smartphones and sales commissions, which could impact cash flow and profitability. Until there is more clarity on these issues, and given the current balance sheet constraints, Diana has opted to maintain a Hold rating on the stock.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.00 price target.
SURG’s price has also changed dramatically for the past six months – from $1.460 to $2.190, which is a 50.0% increase.